Latest & greatest articles for levothyroxine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on levothyroxine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on levothyroxine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for levothyroxine

1. Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels

Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels - GOV.UK GOV.UK uses cookies to make the site simpler. Search Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels Monitor thyroid-stimulating hormone (TSH) in patients treated with levothyroxine for at least the first month (...) after starting and ending ritonavir treatment. Published 11 October 2018 From: Therapeutic area: , , Contents Advice for healthcare professionals: reduced thyroxine levels have been reported in patients concomitantly taking ritonavir-containing products and levothyroxine monitor thyroid-stimulating hormone (TSH) in patients treated with levothyroxine for at least the first month after the start and end of ritonavir treatment report suspected adverse drug reactions resulting from interactions

MHRA Drug Safety Update2018

2. Levothyroxine

Levothyroxine Top results for levothyroxine - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for levothyroxine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical

Trip Latest and Greatest2018

3. Levothyroxine: problems caused by a change in formulation were foreseeable

Levothyroxine: problems caused by a change in formulation were foreseeable Prescrire IN ENGLISH - Spotlight ''Levothyroxine: problems caused by a change in formulation were foreseeable'', 1 February 2018 {1} {1} {1} | | > > > Levothyroxine: problems caused by a change in formulation were foreseeable Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight (...) Levothyroxine: problems caused by a change in formulation were foreseeable The specificities of levothyroxine mean that it was foreseeable that a change in formulation would require a careful rebalancing of the treatment for some patients. Following a change in the formulation of Levothyrox° tablets in France in March 2017, thousands of patients reported suffering from various disorders which they believed were related to the new brand. This change was requested by the French medicines agency in 2012

Prescrire2018

4. Effect of Levothyroxine on Miscarriage Among Women With Normal Thyroid Function and Thyroid Autoimmunity Undergoing In Vitro Fertilization and Embryo Transfer: A Randomized Clinical Trial.

Effect of Levothyroxine on Miscarriage Among Women With Normal Thyroid Function and Thyroid Autoimmunity Undergoing In Vitro Fertilization and Embryo Transfer: A Randomized Clinical Trial. Importance: Presence of thyroid autoantibodies in women with normal thyroid function is associated with increased risk of miscarriage. Whether levothyroxine treatment improves pregnancy outcomes among women undergoing in vitro fertilization and embryo transfer (IVF-ET) is unknown. Objective: To determine (...) the effect of levothyroxine on miscarriage among women undergoing IVF-ET who had normal thyroid function and tested positive for thyroid autoantibodies. Design, Setting, and Participants: An open-label, randomized clinical trial involving 600 women who tested positive for the antithyroperoxidase antibody and were being treated for infertility at Peking University Third Hospital from September 2012 to March 2017. Interventions: The intervention group (n = 300) received either a 25-μg/d or 50-μg/d dose

JAMA2017

5. Immunoallergic reactions with nifuroxazide; adverse effects of levothyroxine

Immunoallergic reactions with nifuroxazide; adverse effects of levothyroxine Prescrire IN ENGLISH - Spotlight ''In the November issue of Prescrire International: immunoallergic reactions with nifuroxazide; adverse effects of levothyroxine'', 1 November 2017 {1} {1} {1} | | > > > In the November issue of Prescrire International: immunoallergic reactions with nifuroxazide; adverse effects of levothyroxine Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |  (...)  |   |   |   |   |   |   |   |  Spotlight In the November issue of Prescrire International: immunoallergic reactions with nifuroxazide; adverse effects of levothyroxine FREE DOWNLOAD This month's sample page from the Adverse Effects section demonstrates the wide range of information available every month in Prescrire International. Full text available for free download. Nifuroxazide: serious immunoallergic reactions Nifuroxazide is used

Prescrire2017

6. Levothyrox (levothyroxine): a change in formulation results in thousands of reports of adverse effects

Levothyrox (levothyroxine): a change in formulation results in thousands of reports of adverse effects Prescrire IN ENGLISH - Spotlight ''Lévothyrox° (levothyroxine): a change in formulation results in thousands of reports of adverse effects'', 18 September 2017 {1} {1} {1} | | > > > Lévothyrox° (levothyroxine): a change in formulation results in thousands of reports of adverse effects Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |    (...) |   |   |   |   |   |   |  Spotlight Lévothyrox° (levothyroxine): a change in formulation results in thousands of reports of adverse effects In France, the lactose in Lévothyrox° (levothyroxine) tablets was replaced by mannitol and citric acid was added as a preservative. According to France's national medicines agency (ANSM), two pharmacokinetics studies demonstrated that the old and the new tablets were bioequivalent. A pharmacovigilance

Prescrire2017

7. Adding carbimazole to levothyroxine increases triiodothyronine and improves outcome in patients with primary hypothyroidism: a preliminary study from Egypt

Adding carbimazole to levothyroxine increases triiodothyronine and improves outcome in patients with primary hypothyroidism: a preliminary study from Egypt 28465796 2018 11 13 2008-5842 9 2 2017 Feb Electronic physician Electron Physician Adding carbimazole to levothyroxine increases triiodothyronine and improves outcome in patients with primary hypothyroidism: a preliminary study from Egypt. 3706-3713 10.19082/3706 Many hypothyroid patients are not tolerant and not satisfied with levothyroxine (...) Salama AS Internal Medicine Department, Faculty of Medicine, Al-Azhar University, New Damietta, Damietta, Egypt. eng Journal Article 2017 02 25 Iran Electron Physician 101645099 2008-5842 Carbimazole Levothyroxine Primary hypothyroidism Triiodothyronine Conflict of Interest: There is no conflict of interest to be declared. 2016 10 08 2017 01 24 2017 5 4 6 0 2017 5 4 6 0 2017 5 4 6 1 epublish 28465796 10.19082/3706 epj-09-3706 PMC5410895 Clin Endocrinol (Oxf). 2008 Nov;69(5):804-11 18410547 J Clin

Electronic physician2017 Full Text: Link to full Text with Trip Pro

10. Randomised controlled trial: Second trimester levothyroxine treatment for subclinical hypothyroidism or hypothyroxinaemia of pregnancy does not improve cognitive outcomes of children

Randomised controlled trial: Second trimester levothyroxine treatment for subclinical hypothyroidism or hypothyroxinaemia of pregnancy does not improve cognitive outcomes of children Second trimester levothyroxine treatment for subclinical hypothyroidism or hypothyroxinaemia of pregnancy does not improve cognitive outcomes of children | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your (...) browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Second trimester levothyroxine treatment for subclinical

Evidence-Based Medicine (Requires free registration)2017

11. Treatment of hypothyroidism with levothyroxine plus liothyronine: a randomized, double-blind, crossover study.

Treatment of hypothyroidism with levothyroxine plus liothyronine: a randomized, double-blind, crossover study. 27982198 2016 12 16 2017 02 08 2359-4292 60 6 2016 Nov-Dec Archives of endocrinology and metabolism Arch Endocrinol Metab Treatment of hypothyroidism with levothyroxine plus liothyronine: a randomized, double-blind, crossover study. 562-572 S2359-39972016000600562 10.1590/2359-3997000000192 To compare the effects of a unique fixed combination levothyroxine/liothyronine (LT4/LT3

Archives of endocrinology and metabolism2016

12. Teva levothyroxine 100 microgram tablets: suspension of marketing authorisation

Teva levothyroxine 100 microgram tablets: suspension of marketing authorisation Teva levothyroxine 100 microgram tablets: suspension of marketing authorisation Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Teva levothyroxine 100 microgram tablets: suspension of marketing authorisation From: Therapeutic area: Following a review by the Commission on Human Medicines (CHM), the marketing authorisation (licence) for levothyroxine 100 microgram tablets manufactured (...) by Teva has been suspended. This article has been superseded. Please see updated information on the , October 2016. Article date: March 2012 Following a review by the Commission on Human Medicines (CHM), the marketing authorisation (licence) for levothyroxine 100 microgram tablets manufactured by Teva has been suspended. The CHM review examined sporadic reports of potential reduced efficacy when switching to Teva levothyroxine from other levothyroxine products and evidence of manufacturing

MHRA Drug Safety Update2012

13. Levothyroxine dose and risk of fractures in older adults: nested case-control study.

Levothyroxine dose and risk of fractures in older adults: nested case-control study. OBJECTIVE: To quantify the effect of levothyroxine dose on risk of fractures in older adults. DESIGN: Nested case-control study. SETTING: Population based health databases, Ontario, Canada. PARTICIPANTS: Adults aged 70 or more prescribed levothyroxine between 1 April 2002 and 31 March 2007 and followed for fractures until 31 March 2008. Cases were cohort members admitted to hospital for any fracture, matched (...) with up to five controls from within the cohort who had not yet had a fracture. MAIN OUTCOME MEASURE: Primary outcome was fracture (wrist or forearm, shoulder or upper arm, thoracic spine, lumbar spine and pelvis, hip or femur, or lower leg or ankle) in relation to levothyroxine use (current, recent past, remote). Risk among current users was compared between those prescribed high, medium, and low cumulative levothyroxine doses in the year before fracture. RESULTS: Of 213,511 prevalent levothyroxine

BMJ2011 Full Text: Link to full Text with Trip Pro

14. Levothyroxine Sodium for Injection

Levothyroxine Sodium for Injection Drug Approval Package: Levothyroxine Sodium NDA #202231 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Levothyroxine Sodium for Injection, 100 mcg, 200 mcg, and 500 mcg vials Company: APP Pharmaceuticals, LLC Application No.: 202231 Approval Date: 06/24/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2011

15. Triiodothyronine levels in athyreotic individuals during levothyroxine therapy.

Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. CONTEXT: Thyroidal production of triiodothyronine (T3) is absent in athyreotic patients, leading to the suggestion that T3 deficiency may be unavoidable during levothyroxine (LT4) therapy. However, trials evaluating therapy with combined LT4 and T3 have failed to demonstrate any consistent advantage of combination therapy. OBJECTIVE: To determine whether T3 levels in patients treated with LT4 therapy were truly

JAMA2008

16. Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism.

Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism. BACKGROUND: Hypothyroidism during pregnancy has been associated with impaired cognitive development and increased fetal mortality. During pregnancy, maternal thyroid hormone requirements increase. Although it is known that women with hypothyroidism should increase their levothyroxine dose during pregnancy, biochemical hypothyroidism occurs in many. In this prospective study we (...) attempted to identify precisely the timing and amount of levothyroxine adjustment required during pregnancy. METHODS: Women with hypothyroidism who were planning pregnancy were observed prospectively before and throughout their pregnancies. Thyroid function, human chorionic gonadotropin, and estradiol were measured before conception, approximately every two weeks during the first trimester, and monthly thereafter. The dose of levothyroxine was increased to maintain the thyrotropin concentration

NEJM2004

17. The effect of levothyroxine therapy on bone mineral density: a systematic review of the literature

The effect of levothyroxine therapy on bone mineral density: a systematic review of the literature The effect of levothyroxine therapy on bone mineral density: a systematic review of the literature The effect of levothyroxine therapy on bone mineral density: a systematic review of the literature Schneider R, Reiners C CRD summary This review assessed the effects of levothyroxine therapy on bone mineral density. The authors concluded that current studies suggest no significant influence (...) of levothyroxine on bone mineral density, but no firm conclusions could be drawn due to the diversity and poor quality of the studies. However, the review itself had some methodological limitations and may not be reliable. Authors' objectives To review the effects of thyroid-stimulating hormone (TSH)-suppressive and replacement levothyroxine therapy on bone mineral density (BMD). Searching MEDLINE was searched from 1990 to 2001; the search terms were reported. The reference lists of retrieved articles were

DARE.2003

18. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial.

Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. 14665656 2003 12 10 2003 12 15 2016 10 17 1538-3598 290 22 2003 Dec 10 JAMA JAMA Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. 2952-8 Standard therapy for patients with primary hypothyroidism is replacement with synthetic thyroxine, which undergoes peripheral conversion (...) to triiodothyronine, the active form of thyroid hormone. Within the lay population and in some medical communities, there is a perception that adding synthetic triiodothyronine, or liothyronine, to levothyroxine improves the symptoms of hypothyroidism despite insufficient evidence to support this practice. To evaluate the benefits of treating primary hypothyroidism with levothyroxine plus liothyronine combination therapy vs levothyroxine monotherapy. Randomized, double-blind, placebo-controlled trial conducted

JAMA2003

19. Starting dose of levothyroxine for the treatment of congenital hypothyroidism: a systematic review

Starting dose of levothyroxine for the treatment of congenital hypothyroidism: a systematic review Starting dose of levothyroxine for the treatment of congenital hypothyroidism: a systematic review Starting dose of levothyroxine for the treatment of congenital hypothyroidism: a systematic review Hrytsiuk I, Gilbert R, Logan S, Pindoria S, Brook C G Authors' objectives To determine the effect of levothyroxine sodium starting dose on cognitive development, growth or behaviour in children (...) of levothyroxine. Participants included in the review Children with congenital hypothyroidism, as identified by neonatal screening, whose global or cognitive development had been assessed using a population-standardised measure. The children included in the review were aged between 1 and 14 years. Outcomes assessed in the review First, the authors compared standardised doses of levothyroxine treatment with the mean standardised development scores in cohorts with different starting doses of levothyroxine

DARE.2002

20. Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analyses

Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analyses Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analyses Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analyses Zelmanovitz F, Genro S, Gross J L Authors' objectives To assess the effect (...) of suppressive doses of levothyroxine (T4) on the volume of benign solitary thyroid nodules (STN) and bone mineral density (BMD). Searching The authors searched the MEDLINE electronic database (January 1985 to December 1997). No further search details are reported. Study selection Study designs of evaluations included in the review Prospective controlled clinical trials with a sufficient dose of T4 for TSH suppression. Additional study inclusion criteria were: 1. A minimum study period of 6 months. 2. STN

DARE.1998